These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38187379)

  • 41. DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis.
    Glossop JR; Nixon NB; Emes RD; Sim J; Packham JC; Mattey DL; Farrell WE; Fryer AA
    Epigenomics; 2017 Apr; 9(4):419-428. PubMed ID: 27885849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A Pharmacogenomics-Driven Machine Learning Approach.
    Myasoedova E; Athreya AP; Crowson CS; Davis JM; Warrington KJ; Walchak RC; Carlson E; Kalari KR; Bongartz T; Tak PP; van Vollenhoven RF; Padyukov L; Emery P; Morgan A; Wang L; Weinshilboum RM; Matteson EL;
    Arthritis Care Res (Hoboken); 2022 Jun; 74(6):879-888. PubMed ID: 34902228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis.
    Singh A; Patro PS; Aggarwal A
    Clin Rheumatol; 2019 Mar; 38(3):877-884. PubMed ID: 30511295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.
    Scrivo R; Conti F; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
    Reumatismo; 2009; 61(2):107-17. PubMed ID: 19633797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers.
    Guan Y; Zhang H; Quang D; Wang Z; Parker SCJ; Pappas DA; Kremer JM; Zhu F
    Arthritis Rheumatol; 2019 Dec; 71(12):1987-1996. PubMed ID: 31342661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
    Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
    Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
    Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
    Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis.
    Sakthiswary R; Shaharir SS; Mohd Said MS; Asrul AW; Shahril NS
    Int J Rheum Dis; 2014 Nov; 17(8):872-7. PubMed ID: 25292482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.
    Feuchtenberger M; Kleinert S; Scharbatke EC; Gnann H; Behrens F; Wittig BM; Greger G; Tony HP
    Clin Exp Rheumatol; 2015; 33(3):321-9. PubMed ID: 25897681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
    Plant D; Maciejewski M; Smith S; Nair N; ; Hyrich K; Ziemek D; Barton A; Verstappen S
    Arthritis Rheumatol; 2019 May; 71(5):678-684. PubMed ID: 30615300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
    Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
    Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.
    Kimura N; Suzuki K; Takeuchi T
    Mod Rheumatol; 2016 Sep; 26(5):676-80. PubMed ID: 26708943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis.
    Iagnocco A; Finucci A; Ceccarelli F; Perricone C; Iorgoveanu V; Valesini G
    Rheumatology (Oxford); 2015 Oct; 54(10):1890-6. PubMed ID: 26070937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis.
    Vassilopoulos D; Gravos A; Vlachopoulos C; Kandili A; Ioakeimidis N; Pectasides D; Stefanadis C
    Clin Rheumatol; 2015 Feb; 34(2):359-64. PubMed ID: 24928345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy.
    McGeough CM; Berrar D; Wright G; Mathews C; Gilmore P; Cunningham RT; Bjourson AJ
    Rheumatol Int; 2012 Jun; 32(6):1647-53. PubMed ID: 21373785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.
    Cuchacovich M; Soto L; Edwardes M; Gutierrez M; Llanos C; Pacheco D; Sabugo F; Alamo M; Fuentealba C; Villanueva L; Gatica H; Schiattino I; Salazaro L; Catalan D; Valenzuela O; Salazar-Onfray F; Aguillón JC
    Scand J Rheumatol; 2006; 35(6):435-40. PubMed ID: 17343250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study.
    Lourido L; Ruiz-Romero C; Picchi F; Diz-Rosales N; Vilaboa-Galán S; Fernández-López C; Tasende JAP; Pérez-Pampín E; Regueiro C; Mera-Varela A; Gonzalez A; Hambardzumyan K; Saevarsdottir S; Nilsson P; Blanco FJ
    Semin Arthritis Rheum; 2020 Oct; 50(5):1101-1108. PubMed ID: 32920323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
    Jani RH; Gupta R; Bhatia G; Rathi G; Ashok Kumar P; Sharma R; Kumar U; Gauri LA; Jadhav P; Bartakke G; Haridas V; Jain D; Mendiratta SK
    Int J Rheum Dis; 2016 Nov; 19(11):1157-1168. PubMed ID: 26176644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.